<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000481.v2.p1" parentStudy="phs000481.v2.p1" createDate="2014-12-09" modDate="2014-12-09">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Ronald M. Krauss, MD</td><td>Children&#39;s Hospital Oakland Research Institute, Oakland, CA</td></tr>
		<tr><td>Co-investigator</td><td>Stephen B. Hulley, MD, MPH</td><td>University of California, San Francisco CA</td></tr>
		<tr><td>Co-investigator</td><td>Joel Simon, MD, MPH</td><td>University of California, San Francisco CA</td></tr>
		<tr><td>Co-investigator</td><td>David Waters, MD</td><td>University of California, San Francisco CA</td></tr>
		<tr><td>Co-investigator</td><td>Mohammed Saad, MD</td><td>University of California, San Francisco CA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Cholesterol and Pharmacogenetics (CAP) Study</StudyNameEntrez>
	<StudyNameReportPage>Cholesterol and Pharmacogenetics (CAP) Study</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Clinical Trial</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 335 African-American and 609 Caucasian (944 total) men and women. Plasma lipids and lipoproteins were measured on two occasions prior to treatment and at 4 and 6 weeks of treatment. The study was designed to test for genetic associations with baseline measurements and changes in response to simvastatin treatment.</p> <p>Whole genome genotyping was performed on 592 Caucasian CAP study participants in two stages. In Stage 1, 304 were genotyped for 314,621 SNPs to tag for common genomic variation. In Stage 2, 290 participants were genotyped, including 280 who were genotyped for 620,901 SNPs. Two samples were excluded due to gender discrepancies.</p> <p>PolyA-selected strand-specific RNA-seq libraries were generated from lymphoblastoid cell lines (LCLs) derived from 104 Caucasian and 53 African American CAP participants. The LCLs were exposed to sham buffer (control) or 2 uM activated simvastatin for 24 hours, producing a total of 314 100/101 bp paired end RNA-seq libraries sequenced on Illumina HiSeq 2000 machines.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion Criteria:</p> <p> <ul> <li>at least 30 years of age</li> <li>Total cholesterol between 160 to 400 mg/dl</li> <li>&#62; 3 grandparents of African-American descent or &#62; 3 grandparents of Caucasian descent</li> <li>serum triglycerides &#60; 400 mg/dl</li> <li>fasting glucose &#60; 126 mg/dl</li> </ul> </p> <p>Exclusion Criteria:</p> <p> <ul> <li>Use of lipid-lowering medication</li> <li>Use of over-the-counter products containing sterol or stanol esters or fish oil</li> <li>Recent or planned change in dietary intake or weight change of more than 4.5 kg</li> <li>Use of corticosteroids, immunosuppressive drugs or drugs affecting the CYP3A4 system</li> <li>Known liver disease or elevated transaminase levels</li> <li>Elevated creatine phosphokinase levels &#62; 10 times upper limits of normal</li> <li>Uncontrolled blood pressure, or diabetes mellitus</li> <li>Abnormal renal or thyroid function</li> <li>Current alcohol or drug abuse</li> <li>Major illness in the preceding three months</li> <li>Pregnancy</li> <li>Know intolerance to statins</li> <li>Racial ancestry other than African-American or Caucasian</li> </ul> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="20339536"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16516587"/>
		</Publication>
		<Publication>
			<Journal authors="Theusch E, Kim K, Stevens K, Smith JD, Chen YI, Rotter JI, Nickerson DA, Medina MW" title="Statin-Induced Expression Change of INSIG1 in Lymphoblastoid Cell Lines Correlates with Plasma Triglyceride Statin Response in a Sex-Specific Manner" journal="In preparation"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Hypercholesterolemia"/>
		<Disease vocab_source="MESH" vocab_term="Cardiovascular Diseases"/>
		<Disease vocab_source="MESH" vocab_term="Hydroxymethylglutaryl-CoA Reductase Inhibitors"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Ronald M. Krauss, MD</AttName>
			<Institution>Children&#39;s Hospital Oakland Research Institute, Oakland, CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Stephen B. Hulley, MD, MPH</AttName>
			<Institution>University of California, San Francisco CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Joel Simon, MD, MPH</AttName>
			<Institution>University of California, San Francisco CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>David Waters, MD</AttName>
			<Institution>University of California, San Francisco CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Mohammed Saad, MD</AttName>
			<Institution>University of California, San Francisco CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Huiying Yang, MD, PhD</AttName>
			<Institution>Cedars-Sinai Medical Center, Los Angeles, CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Jerome I. Rotter, MD</AttName>
			<Institution>Cedars-Sinai Medical Center, Los Angeles, CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Deborah Nickerson, PhD</AttName>
			<Institution>University of Washington, Seattle, WA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Feng Lin, MS</AttName>
			<Institution>University of Washington, Seattle, WA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Stephen Shiboski, PhD</AttName>
			<Institution>University of California, San Francisco CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Patricia J. Blanche, MS</AttName>
			<Institution>Children&#39;s Hospital Oakland Research Institute, Oakland, CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Mathew J. Barber, PhD</AttName>
			<Institution>University of Chicago, Chicago, IL</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Lara M. Mangravite</AttName>
			<Institution>Children&#39;s Hospital Oakland Research Institute, Oakland, CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Craig L. Hyde, PhD</AttName>
			<Institution>Pfizer Global Research and Development, Groton, CT</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Daniel I. Chasman, PhD</AttName>
			<Institution>Brigham and Women&#39;s Hospital, Boston MA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Joshua D. Smith</AttName>
			<Institution>University of Washington, Seattle, WA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Catherine A. McCarty, PhD, MPH</AttName>
			<Institution>Marshfield Clinic Research Foundation, Marshfield, WI</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Xiaohui Li, MD, MS</AttName>
			<Institution>Cedars-Sinai Medical Center, Los Angeles, CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Russell A. Wilke, MD, PhD</AttName>
			<Institution>Vanderbilt University, Nashville, TN</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Mark Rieder, PhD</AttName>
			<Institution>University of Washington, Seattle, WA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Paul T. Williams, PhD</AttName>
			<Institution>Lawrence Berkeley National Laboratory, Berkeley, CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Paul M. Ridker. MD</AttName>
			<Institution>Brigham and Women&#39;s Hospital, Boston MA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Aurobindo Chatterjee PhD</AttName>
			<Institution>Pfizer Global Research and Development, Groton, CT</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Matthew Stephens, PhD</AttName>
			<Institution>University of Chicago, Chicago, IL</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Marisa W. Medina, PhD</AttName>
			<Institution>Children&#39;s Hospital Oakland Research Institute, Oakland, CA</Institution>
		</Header>
		<Header title="Co-investigator">
			<AttName>Elizabeth Theusch, PhD</AttName>
			<Institution>Children&#39;s Hospital Oakland Research Institute, Oakland, CA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01 HL69757</AttName>
			<Institution>National Institutes of Mental Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="Cholesterol and Pharmacogenetic Study (CAP)" url="http://clinicaltrials.gov/show/NCT00451828"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>The trial was conducted between March 2002 and October 2004.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHLBI</DacName>
      <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000481.v2.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000481.v2.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000481.v2.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
